These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 35830772)

  • 1. Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies.
    Osei-Bordom DC; Serifis N; Brown ZJ; Hewitt DB; Lawal G; Sachdeva G; Cloonan DJ; Pawlik TM
    Surg Oncol; 2022 Aug; 43():101803. PubMed ID: 35830772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies.
    Kuznetsova A; Popova O; Panchenkov D; Dyuzheva T; Ivanov A
    Clin Exp Med; 2023 Jul; 23(3):619-643. PubMed ID: 36085429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges.
    Srilatha M; Malla R; Adem MP; Foote JB; Nagaraju GP
    Semin Cancer Biol; 2023 Dec; 97():12-20. PubMed ID: 37926347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
    Bai RL; Wang NY; Zhao LL; Zhang YF; Cui JW
    Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):10-24. PubMed ID: 34538570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreas adenocarcinoma: novel therapeutics.
    Krantz BA; Yu KH; O'Reilly EM
    Chin Clin Oncol; 2017 Jun; 6(3):30. PubMed ID: 28705007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
    Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
    Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
    Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
    Adamska A; Domenichini A; Falasca M
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions.
    Bandi DSR; Sarvesh S; Farran B; Nagaraju GP; El-Rayes BF
    Cytokine Growth Factor Rev; 2023; 71-72():26-39. PubMed ID: 37407355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia and pancreatic ductal adenocarcinoma.
    Yamasaki A; Yanai K; Onishi H
    Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation between gut and intra-tumor microbiota and PDAC: Etiology, diagnostics and therapeutics.
    Qian J; Zhang X; Wei B; Tang Z; Zhang B
    Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188943. PubMed ID: 37355177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity.
    Chamma H; Vila IK; Taffoni C; Turtoi A; Laguette N
    Cancer Lett; 2022 Jul; 538():215694. PubMed ID: 35489447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human microbiota colonization and pancreatic ductal carcinoma.
    Fang Y; Yang G; Yang J; Ren J; You L; Zhao Y
    Crit Rev Microbiol; 2023 Aug; 49(4):455-468. PubMed ID: 35924947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of pancreatic cancer therapy resistance by chemokines.
    Gautam SK; Basu S; Aithal A; Dwivedi NV; Gulati M; Jain M
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):69-80. PubMed ID: 36064086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Treatment Strategies in Pancreatic Cancer.
    Trunk A; Miotke L; Nevala-Plagemann C; Verdaguer H; Macarulla T; Garrido-Laguna I
    Pancreas; 2021 Jul; 50(6):773-787. PubMed ID: 34398070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.